Therapeutic strategies targeting this cycle -such as Nrf2 activators (sulforaphane), mitochondrial antioxidants (MitoQ), and AGE inhibitors (aminoguanidine)- highlight the dual role of OS as interventions early in DM, which can improve β-cell function, while later-stage treatments primarily mitigate complications. This evidence concerns the gene NFE2L2 and diabetes mellitus.